Mass Balance, Pharmacokinetics, and Metabolism of [14C]-Alisertib in Patients With Advanced Solid Tumors or Lymphomas
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2013
At a glance
- Drugs Alisertib (Primary)
- Indications Bladder cancer; Lymphoma; Mesothelioma; Ovarian cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Millennium; Takeda
- 23 Oct 2013 Results for part A presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History